Unknown

Dataset Information

0

Prospective Validation of Pooled Prognostic Factors in Women with Advanced Cervical Cancer Treated with Chemotherapy with/without Bevacizumab: NRG Oncology/GOG Study.


ABSTRACT: PURPOSE:In the randomized phase III trial, Gynecologic Oncology Group (GOG) protocol 240, the incorporation of bevacizumab with chemotherapy significantly increased overall survival (OS) in women with advanced cervical cancer. A major objective of GOG-240 was to prospectively analyze previously identified pooled clinical prognostic factors known as the Moore criteria. EXPERIMENTAL DESIGN:Potential negative factors included black race, performance status 1, pelvic disease, prior cisplatin, and progression-free interval <365 days. Risk categories included low-risk (0-1 factor), mid-risk (2-3 factors), and high-risk (4-5 factors). Each test of association was conducted at the 5% level of significance. Logistic regression and survival analysis was used to determine whether factors were prognostic or could be used to guide therapy. RESULTS:For the entire population (n = 452), high-risk patients had significantly worse OS (P < 0.0001). The HRs of death for treating with topotecan in low-risk, mid-risk, and high-risk subsets are 1.18 [95% confidence interval (CI), 0.63-2.24], 1.11 (95% CI, 0.82-1.5), and 0.84 (95% CI, 0.50-1.42), respectively. The HRs of death for treating with bevacizumab in low-risk, mid-risk, and high-risk subsets are 0.96 (95% CI, 0.51-1.83; P = 0.9087), 0.673 (95% CI, 0.5-0.91; P = 0.0094), and 0.536 (95% CI, 0.32-0.905; P = 0.0196), respectively. CONCLUSIONS:This is the first prospectively validated scoring system in cervical cancer. The Moore criteria have real-world clinical applicability. Toxicity concerns may justify omission of bevacizumab in some low-risk patients where survival benefit is small. The benefit to receiving bevacizumab appears to be greatest in the moderate- and high-risk subgroups (5.8-month increase in median OS). Clin Cancer Res; 21(24); 5480-7. ©2015 AACR.

SUBMITTER: Tewari KS 

PROVIDER: S-EPMC4896296 | biostudies-literature | 2015 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

Prospective Validation of Pooled Prognostic Factors in Women with Advanced Cervical Cancer Treated with Chemotherapy with/without Bevacizumab: NRG Oncology/GOG Study.

Tewari Krishnansu S KS   Sill Michael W MW   Monk Bradley J BJ   Penson Richard T RT   Long Harry J HJ   Poveda Andrés A   Landrum Lisa M LM   Leitao Mario M MM   Brown Jubilee J   Reid Thomas J A TJ   Michael Helen E HE   Moore David H DH  

Clinical cancer research : an official journal of the American Association for Cancer Research 20151201 24


<h4>Purpose</h4>In the randomized phase III trial, Gynecologic Oncology Group (GOG) protocol 240, the incorporation of bevacizumab with chemotherapy significantly increased overall survival (OS) in women with advanced cervical cancer. A major objective of GOG-240 was to prospectively analyze previously identified pooled clinical prognostic factors known as the Moore criteria.<h4>Experimental design</h4>Potential negative factors included black race, performance status 1, pelvic disease, prior ci  ...[more]

Similar Datasets

| S-EPMC6544459 | biostudies-literature
| S-EPMC4479218 | biostudies-literature
| S-EPMC10040434 | biostudies-literature
| S-EPMC7780262 | biostudies-literature
| S-EPMC7907274 | biostudies-literature
| S-EPMC5785748 | biostudies-literature
| S-EPMC5756518 | biostudies-literature
| S-EPMC7201988 | biostudies-literature
| S-EPMC7642021 | biostudies-literature
| S-EPMC8137688 | biostudies-literature